Investigational Drug Information for Itacitinib
✉ Email this page to a colleague
What is the development status for investigational drug Itacitinib?
Itacitinib is an investigational drug.
There have been 53 clinical trials for Itacitinib.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 19th 2017.
The most common disease conditions in clinical trials are Graft vs Host Disease, Primary Myelofibrosis, and Neoplasms. The leading clinical trial sponsors are Incyte Corporation, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There are sixty-five US patents protecting this investigational drug and zero international patents.
Summary for Itacitinib
| US Patents | 65 |
| International Patents | 1,024 |
| US Patent Applications | 306 |
| WIPO Patent Applications | 221 |
| Japanese Patent Applications | 51 |
| Clinical Trial Progress | Phase 3 (2017-07-19) |
| Vendors | 50 |
Recent Clinical Trials for Itacitinib
| Title | Sponsor | Phase |
|---|---|---|
| Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | Incyte Corporation | Phase 1 |
| Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy | Incyte Corporation | Phase 2 |
Clinical Trial Summary for Itacitinib
Top disease conditions for Itacitinib
Top clinical trial sponsors for Itacitinib
US Patents for Itacitinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Itacitinib | ⤷ Sign Up | Bicyclic fused pyrimidine compounds as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
| Itacitinib | ⤷ Sign Up | Benzimidazole derivatives as bromodomain inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Itacitinib | ⤷ Sign Up | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Itacitinib | ⤷ Sign Up | Pyrrolopyrimidine derivatives as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
| Itacitinib | ⤷ Sign Up | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Itacitinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Itacitinib | World Intellectual Property Organization (WIPO) | WO2017027717 | 2035-08-12 | ⤷ Sign Up |
| Itacitinib | Argentina | AR096246 | 2033-05-09 | ⤷ Sign Up |
| Itacitinib | Australia | AU2014262622 | 2033-05-09 | ⤷ Sign Up |
| Itacitinib | Brazil | BR112015028017 | 2033-05-09 | ⤷ Sign Up |
| Itacitinib | Canada | CA2911408 | 2033-05-09 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
